Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial

Family Medicine

Volumn 28, Issue 3, 1996, Pages 204-210

  Simon, Lee S ^a,b   Hatoum, Hind T ^c   Bittman, Richard M ^c   Archambault, W T ^c   Polisson, Richard P ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLON POLYP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENITIS; ESOPHAGITIS; ESOPHAGUS ULCER; FEMALE; FUNCTIONAL DISEASE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH OBSTRUCTION; STOMACH ULCER;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MISOPROSTOL; RISK FACTORS; TREATMENT OUTCOME;

EID: 0030005067     PISSN: 07423225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991;324:1716-25.
2. Furst E. Are there differences among nonsteroidal anti-inflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1994;37:1-9.
3. Abramson SB, Weissman G. The mechanism of action of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1989;32:1-9.
4. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-14.
5. De Win DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 1993;95(suppl 2A):40s-4s.
6. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
7. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide syntheses. J Pharmacol Exp Ther 1994;271:1705-12.
8. Schoen RT, Vender RJ. Mechanisms of nonsteroidal ant-inflammatory drug-induced gastric damage. Am J Med 1989:86:449-58.
9. . Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal antiinflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-19.
10. Lee M, Cryer B, Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994;120:184-9.
11. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med 1994;96:274-81.
12. Simon LS. Toxicity of the nonsteroidal anti-inflammatory drugs. Curr Opin Rheum 1993;5:265-75.
13. Goodman TA. Simon LS. Minimizing the complications of NSAIDs in clinical practice. J Musculoskel Med 1994;11:33-46.
14. Simon LS. Actions and toxicity of the nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1994;6:238-51.
15. Janssen M, Dijkmans BAC, Vandenbroueke JP, et al. Achlorhydria does not protect against benign upper GI ulcers during NSAID use. Dig Dis Sci 1994;39:362-5.
16. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993;88:1318-23.
17. Wilcox CM, Shalek KA, Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper GI hemmorrhage. Arch Intern Med 1994;154:42-6.
18. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Arthritis Rheum 1995;38:5-18.
19. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? J Rheumatol 1991;18:6-10.
20. Fries JP, Miller SR, Spitz PW. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989;96:647-55.
21. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-22.
22. Gabriel SE, Jaakimainen L, Bombadier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
23. Graham DY, Agrawal NM, Roth S. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-80.
24. Agrawal NM, Roth S. Graham DY, et al. Comparison of misoprostol and sucralfate in the prevention of nonsteroidal anti-inflammtory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991;115:195-200.
25. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-62.
26. Elliot SL, Yeomans ND, Buchanan RR, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol 1994;23:171-6.
27. Silverstein FE, Geis GS, Struthers BJ, and the MUCOSA study group. NSAIDs and gastrointestinal injury: clinical outcome, the MUCOSA trial. Gastroenterology 1994;105:A180.
28. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis on nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
29. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
30. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-9.
31. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987;28:527-32.
32. Gabriel SE, Jaakimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
33. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988;109:359-63.
34. Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada. J Clin Epidemiol 1988;41:35-45.
35. Jick SS, Perera DR, Walker AM, Jick H. Nonsteroidal anti-inflammatory drugs and hospital admission for perforated peptic ulcer. Lancet 1987;ii:380-2.
36. Collier DS, Pain JA. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1998;109:359-63.
37. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;10:1079-88.
38. Kurata JH, Nogaws AN, Abbey DE, Petersen F. A prospective study of risk for peptic ulcer disease in Seventh-Day Adventists. Gastroenterology 1992;102:902-9.
39. Caruso I, Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. BMJ 1980;280:75-8.
40. Doherty M, Hunt RH, Langman MJ, et al. Management of NSAID-induced gastrointestinal disturbance. Ann Rheum Dis 1987;46:640-3.
41. Agrawal NM, Roth S, Graham DY, et al. Comparison of misoprostol and sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991;115:195-200.
42. Graham DY, White RH. Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-62.
43. Gabriel SE, Jaakkimainen R, Bombardier C. The cost effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993;36:447-59.
44. Maetzel A, Ferraz MB, Bombardier C. A new examination of the cost-effectiveness of misoprostol in preventing serious gastrointestinal bleeding due to NSAIDs. Arthritis Rheum 1993;38(suppl):S206. Abstract.